Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: food allergy immunotherapeutics - Aimmune Therapeutics/Nestle Health Science

Drug Profile

Research programme: food allergy immunotherapeutics - Aimmune Therapeutics/Nestle Health Science

Alternative Names: Food allergy OIT - Aimmune Therapeutics; Food allergy oral immunotherapies - Aimmune Therapeutics

Latest Information Update: 16 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aimmune Therapeutics
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Food hypersensitivity

Most Recent Events

  • 14 Oct 2020 Aimmune Therapeutics has been acquired by Nestle
  • 28 Oct 2019 No recent reports of development identified for preclinical development in Food-hypersensitivity in USA (PO)
  • 12 Mar 2018 Aimmune Therapeutics intends to file an IND application with the US FDA for AR 301 for food allergy (walnut allergy) in second half of 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top